

**FACT SHEET** As of 12/31/23

# HEALTH CARE ULTRASECTOR PROFUND

## Fund objective

Health Care UltraSector ProFund seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the S&P Health Care Select Sector<sup>SM</sup> Index. The Fund does not seek to achieve its stated investment objective over a period of time greater than a single day.

## Fund details

Inception Date	06/19/2000
Investor Class Symbol	HCPIX
Service Class Symbol	HCPSX
Investor Class Cusip	743185373
Service Class Cusip	743185365
Investor Class Gross Expense Ratio	1.73%
Service Class Gross Expense Ratio	2.73%
Investor Class Net Expense Ratio <sup>1</sup>	1.73%
Service Class Net Expense Ratio <sup>1</sup>	2.73%
Limit on Exchange	None

## Uses for magnified exposure

Common uses for magnified exposure include:

- Seeking magnified gains (will also magnify losses)
- Getting a target level of exposure for less cash
- Overweighting a market segment without additional cash


## Fund performance and index history<sup>2</sup>

The Health Care UltraSector ProFund seeks daily investment results, before fees and expenses, that are 1.5x the return of the S&P Health Care Select Sector Index<sup>SM</sup> Index (the "Index") **for a single day**, not for any other period.

	4Q 2023	Year to Date	1-Year	5-Year	10-Year	Fund Inception
Investor Class NAV Total Return	8.31%	-1.30%	-1.30%	12.14%	12.85%	7.72%
Service Class NAV Total Return	8.04%	-2.29%	-2.29%	11.04%	11.74%	6.68%
S&P Health Care Select Sector	6.41%	2.06%	2.06%	11.58%	11.34%	—
Dow Jones U.S. Health Care	6.44%	1.88%	1.88%	11.08%	11.18%	8.31%

Periods greater than one year are annualized.

## Daily return during 4Q 2023



**Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Performance data current to the most recent month-end is available at Profunds.com or by calling 1-888-776-3637.**

For standardized returns year-to-date, and as of the most recent calendar quarter-end, and annualized month-end, see performance. Returns include the reinvestment of dividends and capital gains.

<sup>1</sup>Contractual waiver effective until November 30, 2024. Without such a waiver of fees, the total returns would have been lower.

<sup>2</sup>All data, unless otherwise noted, is as of 12/31/23, and for Investor Class Shares only. Holdings and other data are subject to change.

Index description <sup>2</sup>																																			
<p>The Index represents the health care sector of the S&amp;P 500 Index ("S&amp;P 500"). The Index is one of eleven S&amp;P Select Sector Indices, each designed to measure the performance of a sector of the S&amp;P 500. The Index includes equity securities of companies from the following Global Industry Classification Standard (GICS®) industries: health care equipment &amp; supplies, health care providers &amp; services; health care technology; biotechnology; pharmaceuticals; and life sciences tools &amp; services.</p>	<div data-bbox="597 96 852 132"> <b>Top index companies <sup>2</sup></b> </div> <div data-bbox="597 142 1520 510"> <table> <thead> <tr> <th></th><th>Weights</th></tr> </thead> <tbody> <tr><td>UnitedHealth Group Inc.</td><td>9.64%</td></tr> <tr><td>Eli Lilly &amp; Co.</td><td>9.20%</td></tr> <tr><td>Johnson &amp; Johnson</td><td>7.47%</td></tr> <tr><td>Merck &amp; Co. Inc.</td><td>5.47%</td></tr> <tr><td>AbbVie Inc.</td><td>5.42%</td></tr> <tr><td>Thermo Fisher Scientific Inc.</td><td>4.06%</td></tr> <tr><td>Abbott Laboratories</td><td>3.78%</td></tr> <tr><td>Pfizer Inc.</td><td>3.22%</td></tr> <tr><td>Amgen Inc.</td><td>3.05%</td></tr> <tr><td>Danaher Corp.</td><td>3.01%</td></tr> </tbody> </table> </div> <div data-bbox="597 541 768 577"> <b>Index sectors <sup>2</sup></b> </div> <div data-bbox="597 585 1156 762"> <table> <thead> <tr> <th></th><th>Weights<sup>3</sup></th></tr> </thead> <tbody> <tr><td>Pharmaceuticals</td><td>29.63%</td></tr> <tr><td>Health Care Providers &amp; Services</td><td>22.52%</td></tr> <tr><td>Health Care Equipment &amp; Supplies</td><td>20.36%</td></tr> <tr><td>Biotechnology</td><td>16.03%</td></tr> <tr><td>Life Sciences Tools &amp; Services</td><td>11.46%</td></tr> </tbody> </table> </div> <div data-bbox="1182 548 1498 867"> </div>		Weights	UnitedHealth Group Inc.	9.64%	Eli Lilly & Co.	9.20%	Johnson & Johnson	7.47%	Merck & Co. Inc.	5.47%	AbbVie Inc.	5.42%	Thermo Fisher Scientific Inc.	4.06%	Abbott Laboratories	3.78%	Pfizer Inc.	3.22%	Amgen Inc.	3.05%	Danaher Corp.	3.01%		Weights <sup>3</sup>	Pharmaceuticals	29.63%	Health Care Providers & Services	22.52%	Health Care Equipment & Supplies	20.36%	Biotechnology	16.03%	Life Sciences Tools & Services	11.46%
	Weights																																		
UnitedHealth Group Inc.	9.64%																																		
Eli Lilly & Co.	9.20%																																		
Johnson & Johnson	7.47%																																		
Merck & Co. Inc.	5.47%																																		
AbbVie Inc.	5.42%																																		
Thermo Fisher Scientific Inc.	4.06%																																		
Abbott Laboratories	3.78%																																		
Pfizer Inc.	3.22%																																		
Amgen Inc.	3.05%																																		
Danaher Corp.	3.01%																																		
	Weights <sup>3</sup>																																		
Pharmaceuticals	29.63%																																		
Health Care Providers & Services	22.52%																																		
Health Care Equipment & Supplies	20.36%																																		
Biotechnology	16.03%																																		
Life Sciences Tools & Services	11.46%																																		
Index Characteristics <sup>2</sup>																																			
<table> <tbody> <tr><td>Number of Companies</td><td>64</td></tr> <tr><td>Price/Earnings Ratio</td><td>19.58</td></tr> <tr><td>Price/Book Ratio</td><td>4.79</td></tr> <tr><td>Dividend Yield</td><td>1.66%</td></tr> <tr><td>Average Market Cap</td><td>\$81.51 billion</td></tr> </tbody> </table>	Number of Companies	64	Price/Earnings Ratio	19.58	Price/Book Ratio	4.79	Dividend Yield	1.66%	Average Market Cap	\$81.51 billion																									
Number of Companies	64																																		
Price/Earnings Ratio	19.58																																		
Price/Book Ratio	4.79																																		
Dividend Yield	1.66%																																		
Average Market Cap	\$81.51 billion																																		
<p>For more information, visit <a href="https://ProFunds.com">ProFunds.com</a> or ask your financial advisor or broker.</p>																																			

Narrowly focused investments typically exhibit higher volatility.

Many ProFunds routinely employ leveraged investment techniques that magnify gains and losses, and result in greater volatility in value. Each geared (leveraged or inverse) ProFund seeks a return that is a multiple (e.g., 2x, -1x) of the return of an index or other benchmark (target) **for a single day**. Due to the compounding of daily returns, geared ProFunds' returns over periods other than one day will likely differ in amount and possibly direction from the target return for the same period. These effects may be more pronounced in funds with larger or inverse multiples and in funds with volatile benchmarks. Investors should monitor their ProFunds holdings consistent with their strategies, as frequently as daily. For more on risks, please read the prospectus.

ProFunds are not suitable for all investors because of the sophisticated techniques the funds employ. Investing involves risk, including the possible loss of principal. ProFunds entail certain risks, including risk associated with the use of derivatives (swap agreements, futures contracts and similar instruments), imperfect benchmark correlation, leverage and market price variance, all of which can increase volatility and decrease performance. For more on correlation, leverage and other risks, please read the prospectus. There is no guarantee any ProFund will achieve its investment objective.

All ProFunds are subject to active investor risk. There are no restrictions on the size and frequency of trades and no transaction fees. The frequent exchanges our policies permit can decrease performance, increase expenses and cause investors to incur tax consequences.

**Carefully consider the investment objectives, risks, charges and expenses of ProFunds before investing. A prospectus or summary prospectus with this and other information may be obtained at [Profunds.com](https://Profunds.com) or by calling 1-888-776-3637. Read them carefully before investing.**

<sup>3</sup>Sum of weightings may not equal 100% due to rounding.

ProFunds are distributed by ProFunds Distributors Inc.© 2023